Title : Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial.

Pub. Date : 2020 Dec 1

PMID : 33270123






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The solute carrier organic anion transporter family member 1B1 (SLCO1B1) genotype is associated with simvastatin myopathy risk and is proposed for clinical implementation. Simvastatin solute carrier organic anion transporter family member 1B1 Homo sapiens
2 The solute carrier organic anion transporter family member 1B1 (SLCO1B1) genotype is associated with simvastatin myopathy risk and is proposed for clinical implementation. Simvastatin solute carrier organic anion transporter family member 1B1 Homo sapiens
3 Overall, 120 participants (29%) had a SLCO1B1 genotype indicating increased simvastatin myopathy risk. Simvastatin solute carrier organic anion transporter family member 1B1 Homo sapiens
4 Among patients with a decreased or poor SLCO1B1 transporter function genotype, simvastatin was prescribed to 1 patient in the control group but none in the intervention group. Simvastatin solute carrier organic anion transporter family member 1B1 Homo sapiens
5 Conclusions and Relevance: Clinical testing and reporting of SLCO1B1 results for statin myopathy risk did not result in poorer ASCVD prevention in a routine primary care setting and may have been associated with physicians avoiding simvastatin prescriptions for patients at genetic risk for SAMS. Simvastatin solute carrier organic anion transporter family member 1B1 Homo sapiens